Remibrutinib
- Generic Name
- Remibrutinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H27F2N5O3
- CAS Number
- 1787294-07-8
- Unique Ingredient Identifier
- I7MVZ8HDNU
- Associated Conditions
- -
- Associated Therapies
- -
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 468
- Registration Number
- NCT06042478
- Locations
- 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 348
- Registration Number
- NCT05976243
- Locations
- 🇺🇸
Allervie Clinical Research, Birmingham, Alabama, United States
🇺🇸Little Rock Allergy and Asthma Clnc, Little Rock, Arkansas, United States
🇺🇸Kern Research, Bakersfield, California, United States
Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT05432388
- Locations
- 🇺🇸
California Allergy and Asthma Medical Group, Los Angeles, California, United States
🇺🇸Allergy and Asthma Clinical Research Inc, Walnut Creek, California, United States
🇺🇸University of Michigan Clinical Trials Office Drug Shipment (3), Ann Arbor, Michigan, United States
Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria
- Conditions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05170724
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT05156281
- Locations
- 🇺🇸
Mayo Clinic Jacksonville ., Jacksonville, Florida, United States
🇺🇸Ctr for Neurology and Spine, Phoenix, Arizona, United States
🇺🇸Vladimir Royter MD APMC, Hanford, California, United States
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT05147220
- Locations
- 🇺🇸
Homestead Assoc In Research Inc, Homestead, Florida, United States
🇺🇸NYU Langone Health Research, Brooklyn, New York, United States
🇺🇸AZ Integrated Neuro and Spine Integrated MS Center, Phoenix, Arizona, United States
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 73
- Registration Number
- NCT04035668
- Locations
- 🇬🇧
Novartis Investigative Site, Tyne And Wear, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.